The proposed legislation to break the patents of Monjauro and Zepbound is facing postponement in the Chamber of Deputies, with discussions now unlikely to take place until after mid-March. The President of the House, Deputy Hugo Motta from the Republican Party of Paraíba, has outlined the priorities for the current legislative week, which include other significant bills such as the Anti-Fake News PL and a tax regime for datacenter services. Plans to expedite the assessment of additional projects are also in motion, but the debate over medication patents appears to be a lower priority for now.

An unofficial source close to Deputy Motta mentioned that the political environment currently lacks urgency for such discussions. The bill, put forward by Deputy Mario Heringer from the Democratic Labor Party of Minas Gerais, had its urgency status approved earlier in the month. However, concerns regarding the costs of the obesity medication both for consumers and for Brazil's Unified Health System (SUS) are pushing the legislative focus towards other matters.

The pharmaceutical sector has expressed strong opposition to the proposal, labeling it as a threat to legal certainty. The high price of the weight-loss pen is cited as a major barrier to broad access for patients, which has raised questions about equity in healthcare access. As the timeline for this critical health policy issue drags on, the implications for future legislative sessions and public health affordability remain significant.